Patient Support for EYLEA® (aflibercept) Injection

EYLEA4U® has support for your patients

EYLEA4U is committed to help ensure your eligible patients have access to EYLEA regardless of insurance or coverage. Our programs include*:

EYLEA Co-Pay Card Program

With the EYLEA Co-Pay Card,
patients with commercial healthcare coverage may be eligible to pay only the first $5 of each treatment's co-pay.^†

See the program

Co-Pay Assistance Referral

EYLEA4U can provide
information about the referral process, which connects patients in need to independent charitable foundations.^‡

Learn about the process

Patient Assistance Program

No insurance or no coverage for EYLEA? No problem. The Patient Assistance Program (PAP) from EYLEA4U can provide EYLEA free of charge to your eligible patients.^§

Get more information

*Program conditions apply.
^†Co-pay reimbursement is subject to an annual cap, and the patient is responsible for any additional co-pay costs that exceed the program assistance limit. This program is not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or similar federal or state programs. This program is not an insurance benefit. The program does not cover or provide support for supplies, procedures, or any physician-related service associated with EYLEA. General, non–product-specific co-pay, co-insurance, or insurance deductibles are not covered. This program is not valid where prohibited by law, taxed, or restricted. EYLEA4U reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Additional program conditions apply.
^‡Regeneron does not influence or control the operations of independent charitable foundations and cannot guarantee assistance will be provided. Subject to Regeneron policies.
^§Household income limits apply.

Did you know? More than 20,000 patients

received support through the EYLEA4U co-pay card program in 2016.

Find the right co-pay support for your patients

Follow this flowchart to determine how to connect your patients to the right program for help with out-of-pocket costs.

^‡Regeneron does not influence or control the operations of independent charitable foundations and cannot guarantee assistance will be provided.

EYLEA4U Enrollment Form

Complete the EYLEA4U Enrollment Form to begin the process of helping your patients determine co-pay assistance eligibility.

Experience what certain retinal diseases can be like in virtual reality

A powerful tool to use with your patients and caregivers, this unique app lets the user experience retinal disease symptoms firsthand in a 360° view. In My Eyes uses virtual reality and augmented reality to show the impact of vision impairment on everyday situations.

Retinal disease virtual and augmented reality app

Product Support

Find complete product support—
guiding you through
orders, returns, and more.

Learn how it works

Reimbursement Support

Get help navigating the
reimbursement process. Find enrollment forms, sample appeal letters, and more.

See the details

News

Keep up to date on
current EYLEA clinical information,
events, and more.

Read the latest

Important Safety Information

EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Intravitreal injections, including those with EYLEA, have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering EYLEA. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately. Intraocular inflammation has been reported with the use of EYLEA.
Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with EYLEA. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with VEGF inhibitors. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). The incidence of reported thromboembolic events in wet AMD studies during the first year was 1.8% (32 out of 1824) in the combined group of patients treated with EYLEA. The incidence in the DME studies from baseline to week 52 was 3.3% (19 out of 578) in the combined group of patients treated with EYLEA compared with 2.8% (8 out of 287) in the control group; from baseline to week 100, the incidence was 6.4% (37 out of 578) in the combined group of patients treated with EYLEA compared with 4.2% (12 out of 287) in the control group. There were no reported thromboembolic events in the patients treated with EYLEA in the first six months of the RVO studies.
Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections with EYLEA including endophthalmitis and retinal detachment.
The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.

Important Prescribing Information

EYLEA® (aflibercept) Injection is indicated for the treatment of patients with

Neovascular (Wet) Age-related Macular Degeneration (AMD): The recommended dose is 2 mg administered by intravitreal injection every 4 weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg once every 8 weeks (2 months). Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every 4 week (monthly) dosing after the first 12 weeks (3 months).
Macular Edema following Retinal Vein Occlusion (RVO): The recommended dose is 2 mg administered by intravitreal injection every 4 weeks (monthly).
Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) in Patients with DME: The recommended dose is 2 mg administered by intravitreal injection every 4 weeks (monthly) for the first 5 injections, followed by 2 mg once every 8 weeks (2 months). Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every 4 week (monthly) dosing after the first 20 weeks (5 months).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.